Thanks techguru. Looks like medical science is ca
Post# of 147659
(Total Views: 649)
Posted On: 12/06/2023 5:03:21 PM
Thanks techguru. Looks like medical science is catching up with the investors on this board. Everyone should read this article.There are only three sources of a safe effective CCR5 antagonists - Bristol Meyers, Maraviroc, and CYDY. The folks on this board have known for a good while which source is preeminently safe and effective.
Excerpt: "...Velasco-Velázquez et al. then concluded that CCR5 antagonists might be used as an adjuvant therapy to reduce the risk of metastasis in patients with the basal breast cancer subtype11. The current study used an assay based on a diagnostic version of PRO140, a CCR5 humanized monoclonal antibody against CCR5 that, in pharmacologic form ( leronlimab) , showed proven efficacy and safety profile. A sub-Q injection form of PRO 140 was tested as monotherapy in HIV-1. It was generally well tolerated relative to placebo and demonstrated potent and prolonged CCR5 blocking activity when administered weekly or every other week16. Therefore, CCR5 inhibitors such as Leronlimab, Maraviroc, and Bristol Myers Squibb BMS-813160 may be potential therapeutic options for patients with UC. Patients may also benefit from a combination of CCR5 inhibitors with currently approved systemic treatment for UC. Functional CCR5 was highly expressed by tumor infiltrating Treg, and CCR5 high Treg was previously shown to be more suppressive than their CCR5 low Treg counterparts17. Therefore, blockade of CCR5 on regulatory T cells (Treg) in combination with PD-L1 blockade could reduce the Treg suppression of CD8 cells and allow the anti-tumor activity of CD8 cells to endure in patients with BC treated with PD-L1 inhibitors such as pembrolizumab and Nivolumab. Also, since CCR5 is expressed on stem-like cancer cells, CCR5 inhibitors may potentiate the response to chemotherapy in the basal type of BC that is generally unresponsive to immunotherapy and thus resembles the basal type of breast cancer..."
Read More: https://investorshangout.com/post/view?id=665...z8L9UzljPd
Bristol Meyers, antagonist.
https://esmed.org/MRA/mra/article/view/4620
Excerpt: "...Velasco-Velázquez et al. then concluded that CCR5 antagonists might be used as an adjuvant therapy to reduce the risk of metastasis in patients with the basal breast cancer subtype11. The current study used an assay based on a diagnostic version of PRO140, a CCR5 humanized monoclonal antibody against CCR5 that, in pharmacologic form ( leronlimab) , showed proven efficacy and safety profile. A sub-Q injection form of PRO 140 was tested as monotherapy in HIV-1. It was generally well tolerated relative to placebo and demonstrated potent and prolonged CCR5 blocking activity when administered weekly or every other week16. Therefore, CCR5 inhibitors such as Leronlimab, Maraviroc, and Bristol Myers Squibb BMS-813160 may be potential therapeutic options for patients with UC. Patients may also benefit from a combination of CCR5 inhibitors with currently approved systemic treatment for UC. Functional CCR5 was highly expressed by tumor infiltrating Treg, and CCR5 high Treg was previously shown to be more suppressive than their CCR5 low Treg counterparts17. Therefore, blockade of CCR5 on regulatory T cells (Treg) in combination with PD-L1 blockade could reduce the Treg suppression of CD8 cells and allow the anti-tumor activity of CD8 cells to endure in patients with BC treated with PD-L1 inhibitors such as pembrolizumab and Nivolumab. Also, since CCR5 is expressed on stem-like cancer cells, CCR5 inhibitors may potentiate the response to chemotherapy in the basal type of BC that is generally unresponsive to immunotherapy and thus resembles the basal type of breast cancer..."
Read More: https://investorshangout.com/post/view?id=665...z8L9UzljPd
Bristol Meyers, antagonist.
https://esmed.org/MRA/mra/article/view/4620
(3)
(0)